TGFB1 and cancer: Indeed, many cancer clinical trials for pharmacological inhibitors targeting the TGF-β signaling have reported side effects, as activation of this molecular pathway is required for normal tissue homeostasis.10 Additionally, whereas many studies have investigated the contribution of EVs to pathological conditions, their role in normal physiology must not be ignored,21 and therapies used to inhibit EV trafficking might also trigger adverse events.